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Summary A toxin(s) has been demonstrated in the
stools of two patients with antibiotic-
associated colitis. This toxin(s) was heat-labile, wasrapidly
lethal for hamsters, increased vascular permeability in
rabbit skin, and was cytotoxic for cells in tissue-culture.
It was neutralised by Clostridium sordellii antitoxin but
not by antitoxins prepared against otherclostridia; Escher-
ichia coli, and Vibrio choler&oelig; toxins. These characteristics
were identical to those of a toxin implicated in the &aelig;tiology
of antibiotic-induced colitis in the hamster. One patient
improved rapidly after treatment with oral vancomycin,
and at the same time the toxin disappeared from the stool.
Introduction -
PSEUDOMEMBRANOUS colitis has been recognised as a
complication of antimicrobial therapy since 1952.’ In
recent years, clindamycin, lincomycin, and ampicillin
have been most frequently associated with this dis-
ease.2.3 While the pathogenesis has remained unclear,
Larson et al. have implicated a heat-labile toxin found
in the faeces of patients with pseudomembranous colitis."
We have demonstrated a similar toxin and its neutralisa-
tion by polyvalent clostridial antitoxin in hamsters with
clindamycin-induced ileoc2ecitis.’ This study shows the
presence of toxin(s) in fasces of two patients with antibi-
otic-associated colitis and the neutralisation of the toxin’
activities by in-vitro incubation with Clostridium sordel-
lii antitoxin. Resolution of the illness and disappearance
of the toxin followed oral vancomycin in one patient.
Patients and Methods
Case I.&mdash;A 12-year-old boy with an imperforate anus un-
derwent closure of his colostomy. He received 1 day of preoper-
tive and 4 days of postoperative clindamycin (total dose 2250
mg) and gentamicin (total dose 150 mg). 1 day after these anti-
biotics were discontinued, he had tarry stools and diarrhoea.
Stool cultures contained no enteric pathogens. During the next
3 weeks he had intermittent fever and respiratory distress. A
barium enema suggested pseudomembranous colitis. On the
27th postoperative day he received one dose of ampicillin (320
mg intravenously), and then chloramphenicol (160 mg intra-
muscularly every 6 hours) and gentamicin (16 mg intra-
venously every 6 hours). His condition’ deteriorated and 24
hours later a laparotomy revealed a diffusely dilated, oedema-
tous colon with a grey pseudomembrane. A sigmoid colostomy
was re-established and a stool sample was obtained for toxicity
studies. He died postoperatively from hypotension and ventri-
cular tachycardia. Pseudomembranous colitis limited to the
colon was confirmed at necropsy.
Case II.&mdash;A 13-year-old girl was transferred from another
hospital on Feb. 5, 1977, with fulminant HBsAg-negative
hepatitis. Stage-iv encephalopathy developed despite treatment
with corticosteroids, oral neomycin, fluids, and nutritional
support. Two exchange transfusions were carried out within
72 hours of admission and within 30 hours she became con-
scious and had no abnormal neurological signs. 3 weeks later,
an 8-day course of ampicillin was given (total dose 70 g) for
a urinary-tract infection. Intermittent abdominal pain, vomit-
ing, and fever developed during treatment. On March 23,
1977, the urinary-tract infection recurred, and she was treated
again with ampicillin (10 g/day) and gentamicin (240 mg/day)
for 14 days. Urinary symptoms and pyuria cleared up, but her
temperature rose to 39.4&deg;C, the abdominal pain increased,
and diarrhoea developed. Sigmoidoscopy with biopsy on April
13, 1977, revealed pseudomembranous colitis. Treatment with
oral vancomycin (500 mg every six hours) was started, and
within 24 hours her diarrhoea ceased. Within 2 days she was
afebrile and without abdominal pain. Vancomycin was con-
tinued for 10 days without complications. Stools were obtained
for study shortly before and again on the 2nd and 4th days of
therapy with vancomycin.
Preparation of stool filtrates.-Fxcal samples from the,
two patients were diluted 1:1 (v/v) with 0.85% NaCl (saline)
and centrifuged at 10 000 g for 30 minutes at 4&deg;C. The super-
natants were then sterilised by filtration through 0.22 &micro;m
millipore membranes and the filtrates stored at -70&deg;C. Control
filtrates were prepared from stool samples of patients with
active ulcerative colitis (4 patients), active granulomatous col-
itis (3), acute salmonella enteritis (1), non-specific enteritis (3),
and normal children (2). Toxicity tests were carried out with
filtrates before and after they had been neutralised or physico-
chemically altered, and with control solutions.
Neutralisation of filtrates.-Filtrates from the two
patients were incubated at room temperature (21&deg;C) for 30
minutes with gas-gangrene polyvalent antitoxin (P.C.A.)
(Lederle, Pearl River, N.J., control no. 339-244); the indivi-
dual U.S. standard clostridial antitoxins contained in P.C.A.
(Cl. perfringens, Cl. septicum, Cl. histolyticus, Cl. cedema-
tiens, and Cl. sordellii) (Dr E. Seligmann, F.D.A., Bureau of
Biologics, Rockville, Md.); Cl. perfringens, Cl. novyi A and B,
and Cl. septicum antitoxins (Burroughs Wellcome Co.,
Research Triangle Park, N.C.); human immune serum globu-
lin (H.I.S.G.) (Merck, Sharp and Dohme, West Point, Pa., con-
trol no. 1170); or mycoplasma-free horse serum (Difco,
Detroit, Mi).
As filtrate from case I was also tested for Esch. colienterotox-
in-like activity, neutralisation of his filtrate was attempted in
Y-1 adrenal cells with heat-labile Esch. coli enterotoxic anti-
sera6 and Swiss Serum Vaccine Institute cholera antiserum
(N.I.H., Bethesda, Md.) by the method of Sack.7
Physicochemical treatment of filtrates.-Filtrates were
heated at 56 &deg;C for 30 minutes, incubated with trypsin (100
ug/ml) or pronase (100 &micro;g/ml) (Sigma Chemical Company, St.
Louis, Mo.) at 37&deg;C for 24 hours, or had their pH adjusted
with 1 mol/1 HCI, or 1 mol/1 NaOH.
Control solutions.-These consisted of solutions of P.C.A.,
H.I.S.G., Cl. sordellii antitoxin, other clostridial antitoxins, pro-
nase, trypsin, and saline.
Toxicity studies in hamsters.-Male golden (Syrian)
hamsters (Charles River Breeding Laboratories, Newfield,
N.J.) weighing 60-90 g were injected intraperitoneally with
10-200 &micro;l of the filtrates or control solutions. Hamsters were
weighed daily, if they became moribund they were killed, and
submitted to necropsy, otherwise necropsies were carried out
within 24 h of death. Tissues were sent for histological exam-
ination.
Assay of vascular permeability factor in rabbit
skin.- New Zealand white rabbits (Langshaw, Augusta, Mi.)
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were depilated and injected intradermally with 100 &micro;1 of
filtrate or control solutions. Evans blue dye (2%) was injected
intravenously 24 hours later; diameters of areas of oedema, of
hmmorrhage, and of increased permeability (seen as "bluing"
due to dye leakage) were measured after 2 hours according to
the method of Evans et al. Each solution was tested in at least
two rabbits and the mean diameter of the lesions was recorded.
Solutions giving a mean diameter of bluing of at least 5 mm
were considered positive for permeability factor.
Assay of cytotoxicity in tissue cultures.--Confluent
monolayers of WI-38 human diploid fibroblasts and hela cells
(HEM Research Inc., Rockville, Md.), were inoculated with 100
fll of filtrate preparations or control solutions and examined
microscopically at 24 and 48 hours. Reactions were graded
visually as: negative = no change in cells; weakly positive =
50-75% cells rounded; positive = 75-100% cells rounded and
monolayer disrupted.
Stool filtrate from case I was tested for Esch. coli heat-labile
enterotoxin-like activity in Y-1 adrenal cells by the method of
Sack and Sack.9
Results
Toxicity for hamsters.-All hamsters injected intra-
peritoneally with 100 &micro;1 of filtrate from case I died
within 24 hours (table I). Weight loss, diarrhoea, haema-
turia, and death within 4 to 10 days occurred in 40% of
animals receiving 10 &micro;1 of filtrate from case I. Necropsies
on hamsters receiving 10 or 100 &micro;1 of filtrate revealed
haemorrhages in the caecum and omental and mesenteric
fat, ileal and caecal distension, and pleural effusions;
blood clots were found in the bladders of those receiving
10 jjLl of filtrate. Microscopic examination confirmed
purulent and haemorrhagic inflammation of the caecum
and serosa.
When 100 &micro;1 of filtrate from case i was incubated with
100 &micro;1 of P.C.A. or H.I.S.G. before injection, the rapidly
lethal response was no longer demonstrable (table I). In-
stead, a toxic syndrome similar to that induced by 10 &micro;1
of untreated filtrate was noted. These observations sug-
gested partial neutralisation of filtrate toxicity. Hamsters
injected with 100 lil of P.C.A. or H.I.S.G. remained well.
Filtrate prepared from the stool of case n (before van-
comycin therapy) was also lethal for hamsters. Intraperi
toneal injection of six animals with 200 &micro;1 of filtrate
from case n killed half the hamsters within 48 hours.
Because only a limited quantity of filtrates from both
cases was available, further toxicity tests in hamsters
could not be carried out.
Stool specimens obtained from case 11 2 and 4 days
after starting vancomycin were not toxic for hamsters
(each specimen was tested in ten hamsters). Groups of
ten hamsters injected with control filtrates or solutions
Of P.C.A. or H.I.S.G. in saline remained well.
Vascular permeability factor assay in rabbit skin.&mdash;
When rabbits were injected intradermally with stool
filtrate from either patient, localised induration and
&oelig;dema developed within 4 hours and reached their max-
imum size by 18-24 hours. Vascular permeability factor
was produced by filtrates from both patients (table n).
Volumes of filtrate (10 &micro;1 of filtrate from case I and 100
&micro;1 of filtrate from case II) that induced areas of oedema
TABLE I-EFFECT OF ANTISERA ON MORTALITY OF HAMSTERS GIVEN CASE-I FILTRATE* INTRAPERITONEALLY
*Filtrate derived from the faeces of case I.
tFiltrate incubated with saline or antisera at 21 &deg;C for 30 min before intraperitoneal injection.
TABLE II&mdash;NEUTRALISATION OF FILTRATE TOXICITY BY ANTISERA AS ASSAYED IN RABBIT SKIN AND TISSUE CULTURES
*Pos.=:5 mm average diameter bluing; Neg.=O mm diameter of bluing.
tPos.=100% of cells rounded and monolayer disrupted; Neg.=normal monolayer.
$1 unit will neutralise 9.3 mgofU.S. standard C/. sordelliitoxin.
&sect;Negative when incubated with 40 &micro;1 human immune serum globulin.
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TABLE III-PHYSICOCHEMICAL PROPERTIES OF STOOL FILTRATES AS ASSAYED IN RABBIT SKIN AND TISSUE CULTURES
*Pos.=5 mm average diameter of bluing; Neg.=0 mm diameter of bluing.
tPos.=100% rounded and monolayer disrupted; Weakly Pos.=50-75% rounded; Neg.=normal monolayer.
with average diameters of at least 15 mm also produced
intradermal haemorrhage and areas of increased permea-
bility with mean diameters of at least 8 mm. These
effects were neutralised (zero mm bluing) by incubation
of the filtrates with P.C.A., H.I.S.G., and Cl. sordellii anti-
toxin. Intradermal reactions produced by the filtrates
were not altered by incubation with normal horse serum
or antisera produced against toxins of Cl. perfringens,
Cl. septicum, Cl. cedematiens, and Cl. histolyticus.
Vascular permeability factor(s) present in these
filtrates was -destroyed by heat, alkalinisation to pH 10
and acidification to pH 5 (table III). Bluing was present
at pH 6. Trypsinisation did not affect the permeability
factor but incubation with pronase decreased the extent
of oedema produced by both filtrates and the capillary
permeability produced by 10 &micro;1 of filtrate from case t (5
mm bluing).
Filtrates prepared from the stool of case n while she
was receiving vancomycin therapy did not contain per-
meability factor. Control filtrates, clostridial antitoxins,
and solutions of trypsin, pronase and saline were also in-
active. 
’
Tissue culture assay.-The toxicity of filtrates from
the two patients for WI-38 human diploid fibroblasts
and hela cells corresponded to activity noted in the rab-
bit skin assay (tables 11 and III). Cl. sordellii antitoxin
was the only clostridial antitoxin that neutralised the
toxicity produced by the two patients’ filtrates. In this
assay, filtrate from case n was more toxic; as little as 1
jil produced cytotoxicity and a greater quantity of
H.I.S.G. was required to neutralise its effect. Both
filtrates were active at pH 5 although the cytotoxicity of
filtrate from case i was reduced at this pH. Treatment
of filtrate from case I with pronase reduced, but did not
abolish, its toxicity.
As with the hamster and rabbit skin assays, filtrates
prepared from case n 2 and 4 days after starting vanco-
mycin were not toxic for cell-cultures. Control filtrates,
antitoxin solutions, pronase and trypsin were also with-
out effect. Cytotoxicity could not be passed serially.
At a dilution of 1:1600, filtrate from case I produced
morphological changes in Y-1 adrenal cells similar to
those seen with Esch. coli heat-labile enterotoxin. Toxi-
city was again neutralised by heating and by incubation
with P.C.A., but antisera to Esch. coli heat-labile enteto-
toxin (1:2 dilution) and to V. cholera (1:10 dilution) did
not neutralise a 1:100 dilution of filtrate from case i.
Discussion
This investigation confirms and extends the findings
of Larson et al. that a heat-labile toxin(s) is present in
the faeces of patients with pseudomembranous colitis in-
duced by clindamycin and ampicillin.4 Our results sug-
gest that the toxin(s) is derived from Cl. sordellii. We
found that this factor(s) was rapidly lethal for hamsters,
produced oedema, haemorrhage and increased vascular
permeability in rabbit skin, and was cytotoxic for
WI-38 and hela cells. Toxic properties were neutralised
by in-vitro incubation of the stool filtrates with Cl. sor-
dellii antitoxin but not with other clostridial, Esch. coli
or V. choler&oelig; antitoxins. The lethal effect of our toxin
on hamsters, its effect on vascular permeability in rabbit
skin, its heat lability, and the pH at which it is effective,
all resemble the properties of Cl. sordellii toxins which
cause either oedema or h&aelig;morrhage.10 Differences in
reactivity noted with the three tests we used might be
due to different amounts of one or more Cl. sordellii
toxins in the two filtrates. In addition, Cl. sordellii toxin
obtained from the F.D.A., when tested in hamsters, rab-
bit skin, and WI-38 and hela cells produced effects iden-
tical to those of filtrates from cases i and n (unpublished
observations).
Cl. sordellii, although pathogenic for man, ’has not
previously been associated with gastrointestinal disease.
Cohn, however, has demonstrated Cl. sordellii toxin pro-
duction in dogs with bowel obstruction," a recognised
cause of colitis.2 His observation and our findings may
point to a common pathogenic mechanism responsible
for the varied illnesses associated with pseudomem-
branous colitis in man and animals.
We have demonstrated that clindamycin-induced col-
itis can be prevented in hamsters by oral vancomycin.12
Furthermore, stool filtrate from hamsters protected by
vancomycin is not toxic by our assays (unpublished
observation). Case n was treated with vancomycin after
the onset of colitis and improved within 24 hours. At the
same time toxin disappeared from stool filtrates. Vanco-
mycin has been reported to be effective in staphylococcal
enterocolitis and pseudomembranous colitis.13 A recent
review has questioned an aetiological role for Staphylo-
coccus aureus in pseudomembranous colitis ;2 we did not
isolate staphylococci from stools of cases I and II, nor
from hamsters with colitis. We do not believe staphylo-
cocci are pathogenically important. Moreover, the re-
sponse to vancomycin therapy reported previously, in
hamsters, and now in one of our patients, warrants a
controlled clinical trial of this drug for the treatment of
antibiotic-induced colitis.
We hope this brief report will siimulate microbiologi-
cal and toxicological studies of all cases of pseudomem-
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branous colitis in order to define more clearly the role
of Cl. sordellii, and possibly that of other toxin-produc-
ing organisms, in this disease.
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CLOFIBRATE INCREASES
LIPOPROTEIN-LIPASE ACTIVITY IN ADIPOSE
TISSUE OF HYPERTRIGLYCERID&AElig;MIC
PATIENTS
K. G. TAYLOR G. HOLDSWORTH
D. J. GALTON
Diabetes and Lipid Laboratory, St. Bartholomew’s Hospital,
London
Summary Clearance of plasma-triglycerides and
activity of lipoprotein lipase in adipose
tissue were studied in six hypertriglycerid&aelig;mic patients
before and after a week of clofibrate therapy (2 g/day).
Plasma-triglycerides decreased significantly from
6&middot;85&plusmn;1&middot;1 to 2&middot;66&plusmn;0&middot;29 mmol/l and triglyceride clear-
ance increased significantly from 1&middot;3&plusmn;0&middot;2 to
2&middot;4&plusmn;0&middot;4%/min. There were concomitant significant in-
creases in heparin-releasable lipoprotein lipase (95&plusmn;16
to 181&plusmn;34 nmol free fatty acids/106 cells/h) and in
extractable lipase (88&plusmn;14 to 179&plusmn;28 nmol free fatty
acids/106 cells/h). It is concluded that an important
effect of clofibrate may be to increase the levels of
adipose-tissue lipoprotein lipase and thereby improve the
clearance of plasma-triglycerides.
Introduction
CLOFiBRATE is extensively used in the treatment of
hypertriglyceridaemias. However, its mechanism of
action is not clearly understood. The possibility that
clofibrate may improve the clearance of very-low-density
lipoprotein (V.L.D.L.) was suggested by the demon-
stration of increased levels of post-heparin plasma-lipo-
protein-lipase activity after treatment with this drug.1-3
Plasma-lipoprotein-lipase catalyses the rate-determining
step for the removal of triglycerides from the blood.
An increase in levels of lipoprotein lipase in adipose
tissue during clofibrate therapy has previously been
observed in the rat,4 but not in man. We have studied
the effect of clofibrate therapy on lipoprotein-lipase acti-
vity in adipose tissue, and plasma-triglyceride clearance
in six hypertriglyceridxmic patients.
Patients and Methods
Six male patients (mean age 51+_2 years, mean weight
76.2&plusmn;33 kg, 14--6% above ideal weight, mean fasting blood-
glucose 5-4+0-8 mmol/1, mean fasting plasma-triglyceride
6.85&plusmn;1.1 mmol/1) were investigated. Before admission to the
study plasma-triglyceride was determined on at least two occa-
sions while the men were fasting. Secondary causes of hyper-
triglyceridsemia such as excess alcohol intake and renal disease
were excluded. Three patients were slightly glucose intolerant.
All were classified as having W.H.O. type iv lipoproteinsemia
by electrophoresis. Informed consent was obtained before hos-
pital admission. None of the patients was receiving drug
therapy, and they were all on unrestricted diets before and
during the period in hospital. The mean weight of the group
decreased to 736&plusmn;3-1 kg (p<0.01) during the week of the
study.
On the day after admission, after an overnight fast, adipose
tissue samples were taken by subcutaneous needle biopsy from
the anterior abdominal wall after 2% lignocaine local an&aelig;sthe-
sia. After a further overnight fast, blood was taken to deter-
mine fasting plasma-triglyceride concentration. An ’Intralipid’
(Vitrum) tolerance test was then performed with 10% intrali-
pid at a dose of 0.1 g/kg.5 From this test a rate constant (k2)
was calculated to express the rate of clearance of intralipid
from the blood, and this has been shown to correlate with the
fractional turnover rate of endogenous triglyceride.6 The
patients remained in hospital and received clofibrate 1 g twice
daily for 7 days, and the studies were repeated.
Lipoprotein lipase released by heparin in vitro was deter-
mined by incubating samples of adipose tissue (100 mg) in
Earle’s bicarbonate buffer pH 7.4 containing 2.5% crystalline
bovine serum albumin with and without heparin (2 U/ml) at
37 &deg;C for 1 h. The media were then assayed for enzyme by
means of a modification of the radiochemical method described
by Krauss et al. The substrate consisted of a triglyceride
emulsion stabilised by lysolecithin. 12.5 mg of glycerol tri-
oleate together with 6 fLCi of glycerol tri[1-’4C]-oleate, and 25
&micro;1 of 5% lysolecithin were ultrasonicated for 4 min at maxi-
mum power by means of an MSE 100 W ultrasonic disintegra-
tor with titanium probe, in a solution of 6 ml of 0.16 mol/1
"tris"/hydrochloric-acid buffer pH 8.1 containing 20 mg of
crystalline bovine serum albumin. 250 &micro;1 of this substrate
emulsion was used in each assay with 100 &micro;1 of normal human
serum taken while fasting, to activate the enzyme. Incubations
were at 37&deg;C for 1 h, and then 200 &micro;1 was extracted in a Bel-
frage Vaughan partition system.8 1 ml of the upper phase was
counted in a Packard liquid scintillation counter model 2420.
Extractable lipase was determined by treating an homo-
genate of adipose tissue (100 mg) with acetone/ether (2/1 v/v).
The extract was then homogenised in a 0.05 mol/1 ammonium-
chloride buffer pH 8.6, and the homogenate assayed for lipo-
protein lipase as above. Adipose-cell size and triglyceride con-
tent were determined,9 enabling results of enzyme activity to
be expressed as a nmol free fatty acid (F.F.A.)/106 cells/h.
Results are expressed as means&plusmn;S.E.M., and significance of dif-
ferences calculated by Student’s paired t test.
Results
Mean fasting plasma triglyceride decreased from
6.85&plusmn;1-1 to 2.66&plusmn;0.29 mmol/1 (P<0.01) and the in-
vivo measurement of triglyceride clearance (k2) in-
creased in all patients (see accompanying table) on clofi-
brate therapy. This was associated with an almost
twofold increase in the activity of adipose-tissue hepar-
in-releasable and cxtractabte lipoprotein lipase (table).
The heparin-releasable lipase increased in all six
